Pharmaceutical Products Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1VNRX Volitionrx
38.44
 0.01 
 7.34 
 0.07 
2VERA Vera Therapeutics
25.69
 0.07 
 4.79 
 0.33 
3VKTX Viking Therapeutics
21.71
 0.16 
 16.48 
 2.68 
4VRCA Verrica Pharmaceuticals
14.83
 0.10 
 3.60 
 0.38 
5EFTR Effector Therapeutics
13.38
(0.10)
 12.27 
(1.20)
6ENGN enGene Holdings Common
10.96
 0.12 
 15.09 
 1.84 
7VCEL Vericel Corp Ord
10.26
 0.04 
 2.12 
 0.09 
8DYAI Dyadic International
8.72
 0.07 
 3.74 
 0.27 
9ELTX Elicio Therapeutics
8.18
 0.20 
 7.23 
 1.41 
10VRTX Vertex Pharmaceuticals
5.83
(0.16)
 1.13 
(0.18)
11DTIL Precision BioSciences
5.18
(0.01)
 6.92 
(0.06)
12VRNA Verona Pharma PLC
5.17
(0.09)
 2.56 
(0.24)
13VSTM Verastem
4.98
(0.07)
 3.79 
(0.28)
14VAXX Vaxxinity
4.58
(0.25)
 9.19 
(2.29)
15SKYE Skye Bioscience, Common
4.49
 0.22 
 14.55 
 3.16 
16VALN Valneva SE ADR
4.3
(0.01)
 3.78 
(0.03)
17VERU Veru Inc
4.28
 0.21 
 9.26 
 1.98 
18VIRX Viracta Therapeutics
3.51
 0.14 
 8.22 
 1.12 
19ELEV Elevation Oncology
3.24
 0.07 
 6.42 
 0.48 
20VCNX Vaccinex
3.05
(0.07)
 6.27 
(0.45)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.